Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

NCT02945267 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Pancreatic Cancer

Interventions

DRUG: Nimotuzumab plus S1
DRUG: Placebo plus S1

Sponsor

Chinese PLA General Hospital